Display options
Cite
Lee LYW, Mohammad S, Starkey T, et al. STAT3 cyclic oligonucleotide decoy-a new therapeutic avenue for NSCLC?. Transl Lung Cancer Res. 2018;7:S381-S384doi: 10.21037/tlcr.2018.09.14.
Lee, L. Y. W., Mohammad, S., Starkey, T., & Lee, S. M. (2018). STAT3 cyclic oligonucleotide decoy-a new therapeutic avenue for NSCLC?. Translational lung cancer research, 7S381-S384. https://doi.org/10.21037/tlcr.2018.09.14
Lee, Lennard Y W, et al. "STAT3 cyclic oligonucleotide decoy-a new therapeutic avenue for NSCLC?." Translational lung cancer research vol. 7 (2018): S381-S384. doi: https://doi.org/10.21037/tlcr.2018.09.14
Lee LYW, Mohammad S, Starkey T, Lee SM. STAT3 cyclic oligonucleotide decoy-a new therapeutic avenue for NSCLC?. Transl Lung Cancer Res. 2018 Dec;7:S381-S384. doi: 10.21037/tlcr.2018.09.14. PMID: 30705862; PMCID: PMC6328701.
Copy Download .nbib Format: NLM
Share it on

Transl Lung Cancer Res. 2018 Dec;7:S381-S384. doi: 10.21037/tlcr.2018.09.14.

STAT3 cyclic oligonucleotide decoy-a new therapeutic avenue for NSCLC?.

Translational lung cancer research

Lennard Y W Lee, Summaya Mohammad, Thomas Starkey, Siow-Ming Lee

Affiliations

  1. Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
  2. Department of Oncology, University College London Hospitals, London, UK.
  3. Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK.

PMID: 30705862 PMCID: PMC6328701 DOI: 10.21037/tlcr.2018.09.14

[No abstract available.]

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

  1. Br J Cancer. 2009 Feb 10;100(3):470-5 - PubMed
  2. Curr Top Microbiol Immunol. 2011;344:41-59 - PubMed
  3. J Surg Res. 2011 Dec;171(2):675-83 - PubMed
  4. Biochem Pharmacol. 2011 Jun 1;81(11):1263-70 - PubMed
  5. Mol Diagn Ther. 2011 Dec 1;15(6):347-52 - PubMed
  6. Cancer Discov. 2012 Aug;2(8):694-705 - PubMed
  7. Int J Oncol. 2012 Oct;41(4):1181-91 - PubMed
  8. Nature. 2012 Sep 27;489(7417):519-25 - PubMed
  9. Exp Cell Res. 2013 Feb 15;319(4):506-16 - PubMed
  10. Mol Cancer Ther. 2013 Oct;12(10):2200-12 - PubMed
  11. Eur J Surg Oncol. 2014 Mar;40(3):311-7 - PubMed
  12. Nature. 2014 Jul 31;511(7511):543-50 - PubMed
  13. Transl Lung Cancer Res. 2015 Jun;4(3):242-52 - PubMed
  14. Cancer Lett. 2016 Aug 28;379(1):124-33 - PubMed
  15. Oncotarget. 2017 Jul 18;8(29):47305-47316 - PubMed
  16. PLoS One. 2017 Aug 10;12(8):e0182282 - PubMed
  17. N Engl J Med. 2017 Nov 16;377(20):1919-1929 - PubMed

Publication Types